[go: up one dir, main page]

MA30076B1 - Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases. - Google Patents

Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.

Info

Publication number
MA30076B1
MA30076B1 MA31060A MA31060A MA30076B1 MA 30076 B1 MA30076 B1 MA 30076B1 MA 31060 A MA31060 A MA 31060A MA 31060 A MA31060 A MA 31060A MA 30076 B1 MA30076 B1 MA 30076B1
Authority
MA
Morocco
Prior art keywords
carbonylaminopyrrolopyrazoles
kinases
powerful inhibitors
inhibitors
formula
Prior art date
Application number
MA31060A
Other languages
English (en)
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Mary Catherine Johnson
Susan Elizabeth Kephart
Haitao Li
Indrawan James Mcalpine
Jayashree Girish Tikhe
Anle Yang
Junhu Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA30076B1 publication Critical patent/MA30076B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases Des carbonylaminopyrrolopyrazoles de formule (I), des compositions comprenant ces composés et des méthodes pour leur utilisation sont proposés. Les composés préférés de formule (I) ont une activité comme inhibiteurs de protéine-kinases, y compris comme inhibiteurs de PAK4.
MA31060A 2005-12-21 2008-06-20 Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases. MA30076B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08

Publications (1)

Publication Number Publication Date
MA30076B1 true MA30076B1 (fr) 2008-12-01

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31060A MA30076B1 (fr) 2005-12-21 2008-06-20 Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.

Country Status (26)

Country Link
US (1) US7884117B2 (fr)
EP (1) EP1979356B1 (fr)
JP (1) JP4635089B2 (fr)
KR (1) KR101029167B1 (fr)
AP (1) AP2369A (fr)
AU (1) AU2006327866B2 (fr)
BR (1) BRPI0620354A2 (fr)
CA (1) CA2634381C (fr)
CR (1) CR10094A (fr)
CU (1) CU23751B7 (fr)
DK (1) DK1979356T3 (fr)
EA (1) EA015513B1 (fr)
EC (1) ECSP088558A (fr)
ES (1) ES2435405T3 (fr)
GE (1) GEP20104974B (fr)
HR (1) HRP20130976T1 (fr)
IL (1) IL191776A (fr)
MA (1) MA30076B1 (fr)
ME (1) MEP0808A (fr)
MY (1) MY151455A (fr)
NO (1) NO20082482L (fr)
NZ (1) NZ568692A (fr)
PL (1) PL1979356T3 (fr)
PT (1) PT1979356E (fr)
RS (2) RS53029B (fr)
WO (1) WO2007072153A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP5868324B2 (ja) * 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
KR20130121122A (ko) 2010-11-17 2013-11-05 에프. 호프만-라 로슈 아게 종양의 치료 방법
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
EP2822935B1 (fr) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-terminale (jnk)
BR112014020173A8 (pt) 2012-03-16 2017-07-11 Hoffmann La Roche Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
EP3057956B1 (fr) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Inhibiteurs polycycliques de la kinase cycline-dépendante 7 (cdk7)
EP3095460A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
EP3095459A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
AU2015337607B2 (en) 2014-10-31 2020-04-09 Ube Corporation Substituted dihydropyrrolopyrazole compound
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP6787314B2 (ja) * 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017144546A1 (fr) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'un carcinome de rhinopharyngite
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
WO2020100944A1 (fr) 2018-11-14 2020-05-22 宇部興産株式会社 Dérivé de dihydropyrrolopyrazole
JP7660063B2 (ja) * 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (fr) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pour le traitement d'une infection par sars-cov-2
WO2022008597A1 (fr) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour le traitement de maladies infectieuses
WO2024261302A1 (fr) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Inhibiteurs de nlrp3, inhibiteurs de pak1/2 et/ou inhibiteurs de caspase 1 pour le traitement de maladies monogéniques liées au rac2
WO2025078334A1 (fr) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combinaison d'inhibiteurs de pak1 et d'inhibiteurs de clk pour prévenir la résistance à la chimiothérapie chez des patients souffrant de leucémie myéloïde aiguë

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143041D1 (de) 2000-08-10 2010-10-21 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP1527074A1 (fr) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles actifs inhibiteurs de kinase, procede de preparation et compositions pharmaceutiques contenant ceux-ci
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
AU2004276341B2 (en) 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
AP2007004061A0 (en) 2005-01-10 2007-08-31 Galloway & Company Pyrrolopyrazoles, potent kinase inhibitors

Also Published As

Publication number Publication date
ECSP088558A (es) 2008-07-30
AP2369A (en) 2012-02-29
AU2006327866B2 (en) 2012-06-14
KR101029167B1 (ko) 2011-04-12
GEP20104974B (en) 2010-04-26
NO20082482L (no) 2008-07-02
WO2007072153A2 (fr) 2007-06-28
IL191776A0 (en) 2008-12-29
ME00006B (fr) 2010-02-10
MEP0808A (xx) 2010-02-10
US7884117B2 (en) 2011-02-08
EP1979356B1 (fr) 2013-09-18
CA2634381A1 (fr) 2007-06-28
ES2435405T3 (es) 2013-12-19
EA200801291A1 (ru) 2008-12-30
US20090318440A1 (en) 2009-12-24
PT1979356E (pt) 2013-11-21
JP4635089B2 (ja) 2011-02-16
CU20080115A7 (es) 2010-08-30
MY151455A (en) 2014-05-30
AP2008004506A0 (en) 2008-06-30
WO2007072153A3 (fr) 2007-10-25
JP2009520805A (ja) 2009-05-28
PL1979356T3 (pl) 2014-01-31
RS20080281A (sr) 2009-09-08
DK1979356T3 (da) 2013-11-18
CU23751B7 (es) 2012-01-31
NZ568692A (en) 2011-07-29
IL191776A (en) 2013-03-24
HK1128290A1 (en) 2009-10-23
BRPI0620354A2 (pt) 2011-11-08
EA015513B1 (ru) 2011-08-30
WO2007072153A8 (fr) 2008-08-14
CA2634381C (fr) 2011-03-08
CR10094A (es) 2008-08-01
EP1979356A2 (fr) 2008-10-15
RS53029B (sr) 2014-04-30
AU2006327866A1 (en) 2007-06-28
KR20080080567A (ko) 2008-09-04
HRP20130976T1 (hr) 2013-11-22

Similar Documents

Publication Publication Date Title
MA30076B1 (fr) Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.
TNSN05208A1 (fr) Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
ATE554087T1 (de) Neue kinaseinhibitoren
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20034289L (no) N-(2-aryletyl)benzylaminer som antagonister av 5-HT6- reseptoren
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
EP1675552A4 (fr) Preparation d'azabenzimidazoles 1,6-disubstitues comme inhibiteurs de kinases
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
TW200621721A (en) Methods of preparing indazole compounds
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
MX2007013238A (es) Derivados de fenilacetileno que tienen afinidad por el receptor mglur5.
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
MX2008001538A (es) Aril piridinas y metodos para su uso.
TN2010000231A1 (fr) Derives de pyrazole servant d'inhibiteurs de 5-lo
MA56441B1 (fr) Carboxamides de thiophène substitués et leurs dérivés comme microbicides
NO20080160L (no) Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser